Abstracts tagged "glucocorticoids"

Abstract Number: 1438 • ACR Convergence 2022
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
Isabell Nevins¹, CF Allaart¹, David Vega Morales², Lai Ling Winchow³, Arvind Chopra⁴, Ana Maria Rodrigues⁵, Tom Huizinga¹, Maarten Boers⁶ and Sytske Anne Bergstra⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Autonomous University of Nuevo León, Monterrey, Mexico, ³Chris hani baragwanath academic hospital, Johannesburg, South Africa, ⁴Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁵Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…
Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Rachel W. Galvao¹, Jeffrey Curtis², Leslie Harrold³, Qufei Wu⁴, Fenglong Xie⁵ and Michael George⁴, ¹Yale University, New Haven, CT, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…
Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
Abstract Number: 0804 • ACR Convergence 2022
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Lifan Zhang¹, yuchen liu², xiaoqing zou³, shi chen², yanan ma², huimin ma⁴, qifei cao⁴, zhengrong yang⁴, Fengchun ZHANG⁵, Yan Zhao⁵, Xiaofeng Zeng⁶ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ³Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: China remains a high-burden country of both rheumatic disease (RD) and tuberculosis (TB) till today. Patients with RD are considered as a high-risk population…
Abstract Number: 1545 • ACR Convergence 2022
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
Despina Michailidou¹, Linda Johansson², Runa Kuley¹, TING WANG¹, Payton Hermanson¹, Solbritt Rantapää-Dahlqvist² and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Neutrophils are important in host defense. However, neutrophil activation has also been involved in the immunopathogenesis of several autoimmune diseases due to their many…
Abstract Number: 0826 • ACR Convergence 2022
Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database
Yuko Kaneko¹, Hideto Kameda², Kei Ikeda³, Katsuhisa Yamashita⁴, Ryoto Ozaki⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Toho University, Tokyo, Japan, ³Chiba University Hospital, Chiba, Japan, ⁴Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁵Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Adult Still's disease (ASD), including adult-onset Still's disease and carry-over systemic juvenile idiopathic arthritis (sJIA), is treated with glucocorticoids (GC) with or without immunosuppressive…
Abstract Number: 1549 • ACR Convergence 2022
Toward Safer Glucocorticoid Therapy
Xingyu Pan¹, Qiongqiong Hou¹, Jiahui Xu¹, Yake Ma¹, Jiawen Li¹, Min Li¹, Jing Su¹, Xuerou Shi¹, William Bracken² and David Katz², ¹WuXi AppTec, Nantong, China, ²Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
Abstract Number: 0831 • ACR Convergence 2022
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Kinza Muzaffar¹, Sulman Hasan², Sarwat umer², Mohammad Alfrad Nobel Bhuiyan², Kavya Vadlamudi², Manush Sondhi², Anusheh Ali¹, Tabitha Muutu² and Samina Hayat¹, ¹Louisiana State University, Shreveport, LA, ²LSU Health Shreveport, Shreveport, LA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…
Abstract Number: 1620 • ACR Convergence 2022
Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Alwin Sebastian¹, alessandro tomelleri², PIERLUIGI MACCHIONI³, Giulia Klinowski³, Carlo Salvarani⁴, Abdul Kayani⁵, Mohammad Tariq⁵, Diana Prieto-Peña⁶, Edoardo Conticini⁷, Muhammad Khurshid⁸, Sue Inness⁹, Jo Jackson⁹, Kornelis van der Geest¹⁰ and Bhaskar Dasgupta⁵, ¹University Hospital Limerick, Dooradoyle, Ireland, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ³IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁴Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁵Mid and South Essex University Hospital Groups, Southend, United Kingdom, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁸University Hospital Dorset, NHS foundation trust, UK, Poole, United Kingdom, ⁹University of Essex, School of Sport, Rehabilitation and Exercise science, Colchester, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for…
Abstract Number: 0767 • ACR Convergence 2021
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Jordan Roberts¹, Laura Berbert¹ and Mary Beth Son², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality, but the extent to which differences in outcomes may be related…
Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 1140 • ACR Convergence 2021
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Alexandra Chop¹, Rajesh Kupuraju¹, Ruchi Patel¹, Kristen Salava¹, Madhuri Duggirala¹, Aparna Baburaj¹, Andrea Berger², Jason Brown¹ and David Bulbin³, ¹Geisinger Medical Center, Danville, PA, ²Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…

« Previous Page
1
…
8
9
10
11
12
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].